低入组因素考量与合理设定入组期方法:日本临床肿瘤学组研究
该研究基于日本临床肿瘤学组1990年1月1日至2021年6月30日启动入组的199项试验,评估低入组风险因素及估算所需入组期的方法。约23.6%的试验在计划入组期内完成。基于既往临床试验入组速度估算的方法有助于按时完成试验(OR 3.51,95%CI 1.73-7.10,P<0.001),而基于参与机构调查评估的方法则不然(OR 1.12,95%CI 0.56-2.26,P=0.751)。
要点
- 约23.6%的试验在计划入组期内完成。
- 计划入组期>3年与试验延长相关(OR 0.37,95%CI 0.15-0.92,P=0.033)。
- 随机III期试验较非随机II期试验延长风险升高(OR 9.29,95%CI 3.39-25.40,P<0.001)。
核心结论
- 若可获得既往试验数据,考虑既往临床试验的入组速度有助于估算所需入组期。
- 开展调查时需警惕高估各机构的病例数。
研究设计与样本
- 研究纳入日本临床肿瘤学组1990年1月1日至2021年6月30日启动入组的199项试验。
- 解释变量包括试验开始前可评估的因素,并评估入组速度估算方法能否在计划入组期内完成。
主要发现
- 约23.6%的试验在计划入组期内完成。
- 计划入组期>3年(参照组≤3年)与试验延长相关:OR 0.37,95%CI 0.15-0.92,P=0.033。
- 分层试验设计(参照组非随机II期)与试验延长相关:非随机III期OR 3.28(95%CI 0.99-10.9,P=0.051),随机II期OR 3.91(95%CI 0.75-20.30,P=0.105),随机III期OR 9.29(95%CI 3.39-25.40,P<0.001)。
- 基于既往临床试验入组速度估算的方法有助于按时完成试验:OR 3.51,95%CI 1.73-7.10,P<0.001。
- 基于参与机构入组速度调查评估的方法:OR 1.12,95%CI 0.56-2.26,P=0.751。
关键数值与推荐
- 约23.6%的试验在计划入组期内完成。
- 计划入组期>3年(参照组≤3年):OR 0.37,95%CI 0.15-0.92,P=0.033。
- 随机III期试验(参照组非随机II期):OR 9.29,95%CI 3.39-25.40,P<0.001。
- 基于既往临床试验入组速度估算:OR 3.51,95%CI 1.73-7.10,P<0.001。
- 基于参与机构调查评估入组速度:OR 1.12,95%CI 0.56-2.26,P=0.751。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poor patient accrual can delay reporting of clinical trials and, consequently, the development of new treatments. For reducing the risk of additional resource requirements, a method for setting planned accrual periods with minimal deviation from the actual accrual periods is desirable. Risk factors for poor patient accrual and the appropriate method of estimating the required accrual period for timely completion of clinical trials were evaluated using the data of trials conducted by the Japan Clinical Oncology Group. METHODS: The study included 199 trials that started patient accrual between January 1, 1990, and June 30, 2021. The explanatory variables included factors that could be evaluated prior to trial commencement. We also evaluated whether the estimation methods for accrual pace could lead to completion within the planned accrual period. RESULTS: Approximately 23.6% of trials were completed within the planned accrual period. The risk factors for trial extension included planned accrual periods > 3 years (reference group: ≤ 3 years, odds ratio [OR] 0.37, 95% confidence interval [CI]: 0.15-0.92, P = 0.033) and stratified trial design (reference group: nonrandomized phase II trials, nonrandomized phase III trial [OR: 3.28, 95% CI: 0.99-10.9, P = 0.051], randomized phase II trial [OR: 3.91, 95% CI: 0.75-20.30, P = 0.105], and randomized phase III trial [OR: 9.29, 95% CI: 3.39-25.40, P < 0.001]). The method of estimating the accrual pace based on past clinical trials facilitated timely completion of the trial (OR: 3.51; 95% CI: 1.73-7.10, P < 0.001), unlike the estimation method based on survey evaluation of the accrual pace for participating institutions (OR: 1.12, 95% CI: 0.56-2.26, P = 0.751). Furthermore, the discrepancy between planned and actual accrual periods was minimal when using the methods of considering the accrual pace of past clinical trials. CONCLUSIONS: Considering the accrual pace of past clinical trials is useful for estimating the required accrual period if data from past trials are available. When conducting a survey, it is necessary to be cautious of overestimating the cases at each facility.
引用
- Sasaki K, Mizusawa J, Bando H, et al. Consideration of factors of low accrual and methods for setting appropriate accrual periods: Japan Clinical Oncology Group study. Trials. 2024. PMID: 39375801. doi:10.1186/s13063-024-08508-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。